Anthera Pharmaceuticals Inc (NASDAQ:ANTH) traded down 9.2% during trading on Thursday . The stock traded as low as $1.65 and last traded at $1.67. 514,614 shares changed hands during trading, an increase of 22% from the average session volume of 420,338 shares. The stock had previously closed at $1.84.

Several equities research analysts have recently commented on the stock. ValuEngine raised shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, December 31st. Zacks Investment Research lowered shares of Anthera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Anthera Pharmaceuticals in a research report on Tuesday, September 19th.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its earnings results on Monday, November 6th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.32. During the same quarter in the previous year, the business earned ($4.85) earnings per share. sell-side analysts expect that Anthera Pharmaceuticals Inc will post -3.09 earnings per share for the current year.

A hedge fund recently raised its stake in Anthera Pharmaceuticals stock. Wedbush Securities Inc. increased its position in Anthera Pharmaceuticals Inc (NASDAQ:ANTH) by 75.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 73,764 shares of the biopharmaceutical company’s stock after acquiring an additional 31,800 shares during the quarter. Wedbush Securities Inc. owned about 0.68% of Anthera Pharmaceuticals worth $106,000 at the end of the most recent quarter. 16.10% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.